|
Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib. |
|
|
Consulting or Advisory Role - Abbvie; Celgene; Genentech; Infinity Pharmaceuticals; Janssen; Merck; Novartis; Pharmacyclics; Seagen; TG Therapeutics |
Research Funding - Pharmacyclics (Inst) |
|
|
Honoraria - Abbvie; Alexion Pharmaceuticals; Gilead Sciences; Janssen; Novartis |
Consulting or Advisory Role - MorphoSys |
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences; Janssen |
|
|
Honoraria - Abbvie; Janssen Oncology |
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Celgene; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Pharmacyclics; Redx Pharma; Roche/Genentech; Sun Pharma |
Research Funding - Gilead Sciences |
|
|
Employment - University of California, Irvine |
Honoraria - Abbvie; Alexion Pharmaceuticals; Amgen; Aptose Biosciences; Astellas Pharma; Celgene; Eisai; Gilead Sciences; GlaxoSmithKline; Janssen; Loxo; Pfizer; Pharmacyclics; Sunesis Pharmaceuticals; TG Therapeutics; Vaniam Group |
Consulting or Advisory Role - Abbvie/Genentech; Alexion Pharmaceuticals; Amgen; Aptose Biosciences; Astellas Pharma; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Pfizer; Pharmacyclics; Sunesis Pharmaceuticals; Sunesis Pharmaceuticals; TG Therapeutics; Vaniam Group |
Research Funding - Acerta Pharma (Inst); Gilead Sciences (Inst); Kite, a Gilead company (Inst); Pfizer (Inst); Pharmacyclics (Inst); Regeneron (Inst); Sunesis Pharmaceuticals (Inst); TG Therapeutics (Inst) |
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Janssen; Janssen Oncology; Regeneron |
|
Jacqueline Claudia Barrientos |
|
Consulting or Advisory Role - Abbvie; Bayer; Genentech; Gilead Sciences; Pharmacyclics |
Research Funding - Pharmacyclics (Inst) |
Travel, Accommodations, Expenses - Janssen |
|
|
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Bristol-Myers Squibb; Celgene |
Speakers' Bureau - Gilead Sciences |
Research Funding - Bristol-Myers Squibb (Inst) |
|
|
Stock and Other Ownership Interests - Pharmacyclics (I) |
Consulting or Advisory Role - Abbvie; BeiGene; Celgene; Genentech/Roche; Gilead Sciences; Janssen Oncology; Novartis; Pharmacyclics |
Research Funding - Abbvie (Inst); Acerta Pharma/AstraZeneca (Inst); Celgene (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Millenium Pharamceuticals (Inst); Pharmacyclics (Inst) |
Travel, Accommodations, Expenses - abbvie; BeiGene; Celgene; Gilead Sciences; Janssen Oncology; Novartis; Pharmacyclics |
|
|
Honoraria - Abbvie; Beigene; Janssen-Cilag; Novartis; Pharmacyclics |
Research Funding - Abbvie (Inst); Janssen-Cilag (Inst) |
|
|
Honoraria - Abbvie; Gilead Sciences; GlaxoSmithKline; Janssen; Roche |
Consulting or Advisory Role - Abbvie; Gilead Sciences; GlaxoSmithKline; Janssen; Roche |
Speakers' Bureau - Abbvie; Gilead Sciences; Janssen; Roche |
Research Funding - Abbvie; Janssen; Roche |
|
|
Honoraria - Abbvie; Amgen; AOP Orphan Pharmaceuticals; Bioverativ; Bristol-Myers Squibb; Celgene; Emergent BioSolutions; Gilead Sciences; Janssen-Cilag; Mundipharma; Novartis; Roche; Sandoz; Takeda; Takeda |
Consulting or Advisory Role - Abbvie; Amgen; Celgene; Gilead Sciences; Novartis; Roche |
Research Funding - Abbvie (Inst); Bioverativ (Inst); Celgene (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Janssen-Cilag (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst) |
|
|
Employment - Moores Cancer Center |
Honoraria - Pharmacyclics/ AbbVie/ Janssen/ Celgene/Genentech/ Roche/ Gilead/ Dava Oncology |
Consulting or Advisory Role - AbbVie/ Pharmacyclics/ Celgene/ Genentech/ Roche/ Leukemia / Janssen/ Dava Oncology/ Gilead |
Speakers' Bureau - Verastem/Pharmacyclics |
Travel, Accommodations, Expenses - Travel/ Honoraria covered by the companies below |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Gilead Sciences; Janssen; Roche |
Consulting or Advisory Role - Abbvie; Gilead Sciences; Janssen; Roche |
Speakers' Bureau - Abbvie; Gilead Sciences; Janssen |
|
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences; Janssen; Roche |
|
|
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Pharmacyclics; Pharmacyclics; Pharmacyclics |
Research Funding - Celgene (Inst); Gilead Sciences (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); TG Therapeutics (Inst) |
|
|
Consulting or Advisory Role - Acerta Pharma; Genentech; Jazz Pharmaceuticals; Pharmacyclics |
Research Funding - Acerta Pharma (Inst); Genentech (Inst); Janssen (Inst); Pharmacyclics (Inst) |
|
|
Honoraria - Abbvie; Janssen; Roche |
Research Funding - Gilead Sciences (Inst); Janssen (Inst); Pharmacyclics (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Abbvie; Janssen |
|
|
Employment - Pharmacyclics |
Stock and Other Ownership Interests - Abbvie |
|
|
Employment - Pharmacyclics |
Stock and Other Ownership Interests - Abbvie |
|
|
Employment - CTI; Pharmacyclics |
Stock and Other Ownership Interests - Abbvie; CTI |
|
|
Research Funding - Abbvie; Acerta Pharma; Janssen; Karyopharm Therapeutics; MorphoSys |